Vioxx Editorial May Bolster Merck Suits
Vioxx Editorial May Bolster Merck Suits
Newsday - Dec 12 6:09 AM
NEW YORK — Merck & Co.’s failure to disclose information about additional heart attacks in a Vioxx clinical trial to a prominent medical journal strengthens plaintiffs’ cases because it bolsters claims that the company deliberately disguised the pain reliever’s risks, experts said.Save to My Web
Vioxx Editorial May Bolster Merck Suits
Newsday - Dec 12 8:04 AM
NEW YORK — Merck & Co.’s failure to disclose information about additional heart attacks in a Vioxx clinical trial to a prominent medical journal strengthens plaintiffs’ cases because it bolsters claims that the company deliberately disguised the pain reliever’s risks, experts said.Save to My Web
Health Business
UPI - Dec 12 10:01 AM
HOUSTON, Dec. 12 (UPI) — The first federal case based on withdrawn painkiller Vioxx has ended in a mistrial. The judge in the Houston-based lawsuit declared a mistrial Tuesday after the jury had been deliberating for about 18 hours, according to published reports.Save to My Web
Medical journal’s editorial on Vioxx evidence may bolster plaintiff cases
phillyburbs.com - Dec 11 3:08 PM
NEW YORK - Merck & Co.’s failure to disclose information about additional heart attacks in a Vioxx clinical trial to a prominent medical journal strengthens plaintiffs’ cases because it bolsters claims that the company deliberately disguised the pain reliever’s risks, experts said.Save to My Web
Vioxx Editorial May Bolster Merck Suits
Newsday - Dec 12 5:45 AM
NEW YORK — Merck & Co.’s failure to disclose information about additional heart attacks in a Vioxx clinical trial to a prominent medical journal strengthens plaintiffs’ cases because it bolsters claims that the company deliberately disguised the pain reliever’s risks, experts said.Save to My Web